WO2023241390A1 - Compositions and uses thereof - Google Patents
Compositions and uses thereof Download PDFInfo
- Publication number
- WO2023241390A1 WO2023241390A1 PCT/CN2023/098264 CN2023098264W WO2023241390A1 WO 2023241390 A1 WO2023241390 A1 WO 2023241390A1 CN 2023098264 W CN2023098264 W CN 2023098264W WO 2023241390 A1 WO2023241390 A1 WO 2023241390A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- ssp
- bifidobacterium
- enteral
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 184
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 34
- 239000006041 probiotic Substances 0.000 claims abstract description 33
- 235000018291 probiotics Nutrition 0.000 claims abstract description 33
- 230000000529 probiotic effect Effects 0.000 claims abstract description 29
- 241000894006 Bacteria Species 0.000 claims abstract description 27
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 26
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 18
- 239000000835 fiber Substances 0.000 claims abstract description 15
- 206010006326 Breath odour Diseases 0.000 claims abstract description 13
- 230000003860 sleep quality Effects 0.000 claims abstract description 13
- 208000032139 Halitosis Diseases 0.000 claims abstract description 12
- 230000037075 skin appearance Effects 0.000 claims abstract description 8
- 230000001332 colony forming effect Effects 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 19
- 150000001720 carbohydrates Chemical class 0.000 claims description 13
- 235000014633 carbohydrates Nutrition 0.000 claims description 13
- 235000016709 nutrition Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 7
- 241000894007 species Species 0.000 claims description 7
- 229920002498 Beta-glucan Polymers 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 5
- 229940029339 inulin Drugs 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229920001202 Inulin Polymers 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000036548 skin texture Effects 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 2
- 241000186012 Bifidobacterium breve Species 0.000 claims description 2
- 241000185999 Bifidobacterium longum subsp. longum Species 0.000 claims description 2
- 241000186148 Bifidobacterium pseudolongum Species 0.000 claims description 2
- 241000186660 Lactobacillus Species 0.000 claims description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229940039696 lactobacillus Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940000425 combination drug Drugs 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 abstract description 16
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 9
- 229920001542 oligosaccharide Polymers 0.000 description 7
- 206010062519 Poor quality sleep Diseases 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000012907 honey Nutrition 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000008447 perception Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000019722 synbiotics Nutrition 0.000 description 3
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 2
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical group C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 2
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 2
- RTVRUWIBAVHRQX-PMEZUWKYSA-N Fucosyllactose Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]1O)O)OC)O[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O RTVRUWIBAVHRQX-PMEZUWKYSA-N 0.000 description 2
- 240000003394 Malpighia glabra Species 0.000 description 2
- 235000014837 Malpighia glabra Nutrition 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 2
- 229940062780 lacto-n-neotetraose Drugs 0.000 description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 2
- 229960000511 lactulose Drugs 0.000 description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 2
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- KJLPSBMDOIVXSN-UHFFFAOYSA-N 4-[4-[2-[4-(3,4-dicarboxyphenoxy)phenyl]propan-2-yl]phenoxy]phthalic acid Chemical compound C=1C=C(OC=2C=C(C(C(O)=O)=CC=2)C(O)=O)C=CC=1C(C)(C)C(C=C1)=CC=C1OC1=CC=C(C(O)=O)C(C(O)=O)=C1 KJLPSBMDOIVXSN-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- 235000021310 complex sugar Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229940037201 oris Drugs 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 235000021580 ready-to-drink beverage Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 235000021269 warm food Nutrition 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
Definitions
- the present invention relates to compositions for preventing or treating insomnia, improving skin appearance, reducing halitosis and increasing relaxation towards sleep, improving sleep quality.
- CN104187613 discloses a nutritional recipe for insomnia comprising Chinese medicines, probiotics, water soluble prebiotic fibres, etc.
- CN107496850 discloses a preparation for regulating intestinal microecology with ginseng to calm the verse, and then to help on enhancing sleep.
- CN107874251 disclosed a chili probiotic composition
- a chili probiotic composition comprising 1-9 parts of Chinese herbal extract, 0.01-2 parts of food grade probiotics and 0.1-5 parts of prebiotics.
- the present invention relates to a composition for use in preventing and/or treating insomnia in a human subject, the composition comprising:
- the inventors surprisingly observed remarkable improvements in skin appearance and condition, and reduced halitosis.
- the present invention relates to a non-therapeutic method of reducing halitosis, the method comprising administration of a composition to a human subject in need thereof, wherein the composition comprises:
- composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacil-lus ssp., Bifidobacterium ssp., or combinations thereof; and optionally
- Halitosis reduction is herein defined in comparison with a subject not administered with the composition according to the invention. It can be determined by individual perception as assessed by specialized questionnaire, or by dental care professional.
- the present invention relates to a non-therapeutic method of improving skin appearance and texture, the method comprising administration of a composition to a human subject in need thereof, wherein the composition comprises:
- composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacil-lus ssp., Bifidobacterium ssp., or combinations thereof; and optionally
- composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacillus ssp., Bifidobacterium ssp., or combinations thereof
- composition does not comprise lactose.
- the composition is preferably a synbiotic composition.
- the composition is an enteral composition, preferably an oral composition.
- Prevention refers to reduction in the likelihood of developing a certain condition or symptom associated with a condition in subjects in need thereof or particularly at risk of developing said symptoms and conditions.
- Treatment refers to the reduction, alleviation or complete removal of symptoms associated with certain conditions causing human suffering or discomfort.
- “Insomnia” is a common sleep disorder characterized by the difficulty in falling asleep, staying asleep, or causing the affected subject to wake up too early and not be able to get back to sleep, and unsatisfactory proportion of deep or restorative sleep. Induction of pre-sleep relaxation increases quality and duration of sleep, helping to increase the overall sensation of feeling rested after sleep. It can be diagnosed and assessed by general practitioner or medical specialist in sleep and correlate conditions.
- improving sleep quality and/or induction and/or enhancement of pre-sleep relaxation is in comparison to a human taking no nutritional composition comprising a and b (i.e., no composition or taking another composition not comprising a and b) .
- the improvement in the human taking the nutritional composition comprising a and b increases ⁇ 2%, preferably ⁇ 5%, more preferably ⁇ 50%, even more preferably ⁇ 65%.
- Halitosis is a condition characterized by oral malodor and is not necessarily linked to oral and dental diseases.
- Halitosis may be of either intra-oral or extra-oral origin.
- Extra-oral (non-oral) halitosis may be from gastrointestinal origin.
- the inventors have surprisingly observed a reduction in halitosis in subjects administered the composition according to the invention. Without wishing to be bound any theory, it is hypothesized that the composition according to the invention prevents dysbiosis in the gastrointestinal tract, thereby removing extra-oral causes of halitosis.
- “Skin appearance and texture” refers to the improved perception of skin upon consumption of the composition according to the invention. Particularly, the inventors have surprisingly observed that adults who consumed the composition of the invention claimed a significant improvement on the skin appearance and reduction of large skin pores.
- the present invention is defined as a method of preventing and/or treating insomnia in a human subject, the method comprising the administration of a composition to the human subject, the composition comprising:
- composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacil-lus ssp., Bifidobacterium ssp., or combinations thereof; and optionally
- the present invention is defined as the use of a composition in the manufacture of a composition for preventing and/or treating insomnia in a human subject, the composition comprising:
- composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacil-lus ssp., Bifidobacterium ssp., or combinations thereof; and optionally
- composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacil-lus ssp., Bifidobacterium ssp., or combinations thereof; and optionally
- prevention and/or treatment is in comparison to a human taking no nutritional composition comprising a and b (i.e., no composition or taking another composition not comprising a and b) .
- the improvement to preventing and/or treating insomnia (including poor sleep) in the human taking the nutritional composition comprising a and b increases ⁇ 2%, preferably ⁇ 5%, more preferably ⁇ 50%, even more preferably ⁇ 65%.
- the composition comprises 10 3 to 10 12 colony forming units per gram of composition of at least a probiotic bacteria, more preferably 10 4 to 10 10 colony forming units per gram of composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacillus ssp., Bifidobacterium ssp., or combinations thereof.
- the composition comprises 1-20 wt. %of at least a probiotic bacteria, based on dry weight of the composition, more preferably 3-15 wt. %of at least a probiotic bacteria, based on dry weight of the composition.
- the composition comprises 25-250 mg of at least a probiotic bacteria per gram of the composition, more preferably 50-150 mg of at least a probiotic bacteria per gram of the composition.
- the daily dose of the at least one probiotic bacteria in the composition according to the invention in an amount from 10 3 to 10 12 colony forming units, preferably 10 8 to 10 11 colony forming units.
- the composition comprises at least one species of Lacticaseibacillus ssp.
- Lacticaseibacillus ssp present in the composition is selected from the group comprising: Lacticaseibacillus paracasei, Lacticaseibacillus acidophillus, Lacticaseibacillus murinus, Lacticaseibacillus reuteri, Lacticaseibacillus rhamnosus, or mixtures thereof.
- the probiotic bacteria comprises Lacticaseibacillus paracasei subsp. paracasei, more preferably Lacticaseibacillus paracaseisubsp. paracasei CRL 431.
- the composition may comprise at least one species of Bifidobacterium ssp.
- Bifidobacterium ssp Preferred species of Bifidobacterium ssp. Include: Bifidobacterium adolescentis, Bifidobacterium longum subsp. longum, Bifidobacterium subsp. infantis, Bifidobacterium pseudolongum, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium animalis subsp. lactis, Bifidobacterium breve, and mixtures thereof.
- the Bifidobacterium ssp. is Bifidobacterium lactis BB12 (as deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under deposit number DSM 15954) , commercially available by Christian Hansen company of Denmark under the trade mark Bb12.
- the composition comprises at least one species of Lactobacillus ssp. and one species of Bifidobacterium ssp. More preferably, the composition comprises a mixture of Lacticaseibacillus paracasei subsp. paracasei CRL 431 and Bifidobacterium lactis BB12.
- the composition comprises carbohydrates, including the prebiotic fibres.
- the composition comprises ⁇ 11 wt%of prebiotic fibres, more preferably ⁇ 30 wt%, even more preferably ⁇ 40 wt%, especially more preferably 60-90 wt%of prebiotic fibre based on total weight of the composition.
- total carbohydrates are present in an amount ranging from 40 –98 wt. %by weight of total composition, more preferably 50-95 wt. %by weight of total composition.
- the composition does not comprise lactose and milk-derived carbohydrates, preferably the composition does not comprise lactose.
- the prebiotic fibres are preferably soluble prebiotic fibres.
- “Soluble prebiotic fibres” herein also referred to non-digestible fibres, are beneficially affect the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria in the colon, and thus improving host health.
- Such ingredients are non-digestible in the sense that they are not broken down and absorbed in the stomach or small intestine and thus pass intact to the colon where they are selectively fermented by the beneficial bacteria.
- the composition may further comprise 1-10wt%juice powder, more preferably 2-8wt%of a juice powder, based on total weight.
- a preferred juice powder is acerola juice powder.
- the human subject is selected from a toddler, adolescent or adult.
- the composition according to the invention is for administration in a human older than 3 years of age, preferably older than 6 years of age, more preferably older than 12 years of age, more preferably older than 16 years of age.
- the human volunteers were aged between 40-60 years old (mean of 49 years) wherein 49%were male and 51%were female participants.
Abstract
The compositions for preventing or treating insomnia, improving sleep quality, improving skin appearance, reducing halitosis and increasing relaxation towards sleep, improving sleep quality. In particular, the compositions comprise a probiotic bacteria selected from the group comprising: Lacticaseibacillus ssp., Bifidobacterium ssp., or combinations thereof; and optionally a prebiotic fibre.
Description
The present invention relates to compositions for preventing or treating insomnia, improving skin appearance, reducing halitosis and increasing relaxation towards sleep, improving sleep quality.
The amount of sleep hours varies per person. For most adults, seven to eight hours per night is considered necessary. As aging occurs, internal sleep clock starts to lose consistency. Older adults thus tend to become tired earlier in the evening and wake up earlier in the morning, resulting in less sleep overall and increasing the risk of cognitive decline. Elderly people experiencing Alzheimer’s , dementia, or other neu-rodegenerative diseases experience even more severe changes in sleep drive.
An increasing part of the adult population will, at some point in life, experience short-term, acute insomnia which lasts for days or weeks. This is usually the result of a stressful or a traumatic event. However, some people suffer from long-term, chronic insomnia, wherein insomnia itself may be the primary problem, or it may be associ-ated with other medical conditions or medications.
Data shows that more than 300 million Chinese people experience poor sleep quality, sleep disorders or insomnia. Individuals suffering from poor sleep quality or insomnia often still feel tired after waking up, and experience negative impacts on energy lev-el, mood and overall health, work performance and quality of life.
The large group of individuals suffering from poor sleep quality and/or insomnia has driven the consumption of sleep-aid products. In recent years, various types of sleep monitoring and support softwares have been launched in major APP stores. Moreo-ver, latex pillows, sleep aids, aromatherapy lamps, melatonin, sleep gummies, and other products are commonly sought for to help the sleep.
CN104187613 discloses a nutritional recipe for insomnia comprising Chinese medicines, probiotics, water soluble prebiotic fibres, etc.
CN107496850 discloses a preparation for regulating intestinal microecology with ginseng to calm the verse, and then to help on enhancing sleep.
CN107874251 disclosed a bazhen probiotic composition comprising 1-9 parts of Chinese herbal extract, 0.01-2 parts of food grade probiotics and 0.1-5 parts of prebiotics.
Adults especially aging people suffer more of poor sleep due to various reasons, e.g. pressure from work, depression from lockdown, inter-personal disputes, etc. However, there is a reluctancy to seek for pharmacological treatment. There thus remains the need for improved nutritional interventions to induce relaxation and treat insomnia with an easy and convenient way.
In a study with over 200 human adults, the inventors have observed a substantial improvement in the sleep induction and quality, mood and a reduction on psychological stress when subjects were administered a composition comprising a combination of prebiotic soluble fibres and probiotic bacterial strains. Unexpectedly, this improvement was observed within 7 days from the start of consumption of the composition according to the invention.
Accordingly, in one aspect, the present invention relates to a composition for use in preventing and/or treating insomnia in a human subject, the composition comprising:
a. 103 to 1012 colony forming units per gram of composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacil-lus ssp., Bifidobacterium ssp., or combinations thereof; and, optionally,
b. ≥ 11 wt%prebiotic fibre based on the total weight of the composition.
In a second aspect, the present invention relates to a non-therapeutic method of improving sleep quality and/or inducing and/or enhancing pre-sleep relaxation, the method comprising administration of a composition to a human subject in need thereof, wherein the composition comprises:
a. 103 to 1012 colony forming units per gram of composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacil-lus ssp., Bifidobacterium ssp., or combinations thereof; and optionally
b. ≥ 11 wt%prebiotic fibre, based on the total weight of the composition.
Herein, induction and/or enhancement of pre-sleep relaxation is in comparison with a human subject not administered with the composition according to the invention. It can be determined by individual perception as assessed by specialized questionnaire (including digital) , or by psychological and mental care professional.
Moreover, the inventors surprisingly observed remarkable improvements in skin appearance and condition, and reduced halitosis.
In a third aspect, the present invention relates to a non-therapeutic method of reducing halitosis, the method comprising administration of a composition to a human subject in need thereof, wherein the composition comprises:
a. 103 to 1012 colony forming units per gram of composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacil-lus ssp., Bifidobacterium ssp., or combinations thereof; and optionally
b. ≥ 11 wt%prebiotic fibre based on the total weight of the composition.
Halitosis reduction is herein defined in comparison with a subject not administered with the composition according to the invention. It can be determined by individual perception as assessed by specialized questionnaire, or by dental care professional. In a fourth aspect, the present invention relates to a non-therapeutic method of improving skin appearance and texture, the method comprising administration of a composition to a human subject in need thereof, wherein the composition comprises:
a. 103 to 1012 colony forming units per gram of composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacil-lus ssp., Bifidobacterium ssp., or combinations thereof; and optionally
b. ≥ 11 wt%prebiotic fibre based on the total weight of the composition.
Improvement in skin appearance and texture is herein defined in comparison with a subject not administered with the composition according to the invention. It can be determined by individual perception as assessed by specialized questionnaire, or by skin care professional such as aesthetician.
In a fifth aspect, the present invention relates to a composition comprising:
i. at least 40 wt. %carbohydrates, based on total weight of the composition,
ii. ≥85 wt. %prebiotic soluble fibres, based on total weight of carbohydrates,
iii. 103 to 1012 colony forming units per gram of composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacillus ssp., Bifidobacterium ssp., or combinations thereof
wherein the composition does not comprise lactose.
In all aspects of the invention, the composition is preferably a synbiotic composition.
As defined herein, the composition is an enteral composition, preferably an oral composition.
"Probiotic" means microbial cell preparations or components of microbial cells with a beneficial effect on the health or well-being of the host. (Salminen S, Ouwehand A. Benno Y. et al "Probiotics: how should they be defined" Trends Food ScL Technol. 1999: 10 107-10) .
“Synbiotic” as used herein refers to a composition comprising a combination of probiotic microorganisms and prebiotic components.
“Prevention” as used herein refers to reduction in the likelihood of developing a certain condition or symptom associated with a condition in subjects in need thereof or particularly at risk of developing said symptoms and conditions. “Treatment” as used herein refers to the reduction, alleviation or complete removal of symptoms associated with certain conditions causing human suffering or discomfort.
“Insomnia” is a common sleep disorder characterized by the difficulty in falling asleep, staying asleep, or causing the affected subject to wake up too early and not be able to get back to sleep, and unsatisfactory proportion of deep or restorative sleep. Induction of pre-sleep relaxation increases quality and duration of sleep, helping to increase the overall sensation of feeling rested after sleep. It can be diagnosed and assessed by general practitioner or medical specialist in sleep and correlate conditions.
As used herein, “sleep quality” refers to quantitative aspects of sleep, such as sleep duration, sleep latency, or number of arousals, as well as subjective aspects, such as depth or restfulness of sleep. Sleep quality can be determined by Pittsburgh Sleep Quality Index (Buysee et al. “The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research” . Psych Res, 28, 193-213.1989) .
Herein, improving sleep quality and/or induction and/or enhancement of pre-sleep relaxation is in comparison to a human taking no nutritional composition comprising a and b (i.e., no composition or taking another composition not comprising a and b) . Accordingly, in comparison to a human taking no nutritional composition comprising a and b (i.e., no composition or taking another composition not comprising a and b) , the improvement in the human taking the nutritional composition comprising a and b increases ≥ 2%, preferably ≥ 5%, more preferably ≥ 50%, even more preferably ≥65%. Specifically, if the improvement to a human taking no nutritional composition comprising a and b (or taking another composition not comprising a and b) is M, and the improvement as compared to the human taking the nutritional composition comprising a and b is N, then: (N-M) /N*100%is the percentage it increases.
“Halitosis” (fetor oris or bad breath) is a condition characterized by oral malodor and is not necessarily linked to oral and dental diseases. Halitosis may be of either intra-oral or extra-oral origin. Extra-oral (non-oral) halitosis may be from gastrointestinal origin. The inventors have surprisingly observed a reduction in halitosis in subjects administered the composition according to the invention. Without wishing to be bound any theory, it is hypothesized that the composition according to the invention prevents dysbiosis in the gastrointestinal tract, thereby removing extra-oral causes of halitosis.
“Skin appearance and texture” refers to the improved perception of skin upon consumption of the composition according to the invention. Particularly, the inventors have surprisingly observed that adults who consumed the composition of the invention claimed a significant improvement on the skin appearance and reduction of large skin pores.
In some jurisdictions, the present invention is defined as a method of preventing and/or treating insomnia in a human subject, the method comprising the administration of a composition to the human subject, the composition comprising:
a. 103 to 1012 colony forming units per gram of composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacil-lus ssp., Bifidobacterium ssp., or combinations thereof; and optionally
b. ≥ 11 wt%prebiotic fibre based on the total weight of the composition.
In other jurisdictions, the present invention is defined as the use of a composition in the manufacture of a composition for preventing and/or treating insomnia in a human subject, the composition comprising:
a. 103 to 1012 colony forming units per gram of composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacil-lus ssp., Bifidobacterium ssp., or combinations thereof; and optionally
b. ≥ 11 wt%prebiotic fibre based on the total weight of the composition.
In further jurisdictions, the present invention is defined as the non-therapeutic method of preventing and/or treating insomnia in a human subject, the composition comprising:
a. 103 to 1012 colony forming units per gram of composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacil-lus ssp., Bifidobacterium ssp., or combinations thereof; and optionally
b. ≥ 11 wt%prebiotic fibre based on the total weight of the composition.
Preferably, prevention and/or treatment is in comparison to a human taking no nutritional composition comprising a and b (i.e., no composition or taking another composition not comprising a and b) . Accordingly, in comparison to a human taking no nutritional composition comprising a and b (i.e., no composition or taking another composition not comprising a and b) , the improvement to preventing and/or treating insomnia (including poor sleep) in the human taking the nutritional composition comprising a and b increases ≥ 2%, preferably ≥ 5%, more preferably ≥ 50%, even more preferably ≥ 65%. Specifically, if the improvement to a human taking no nutritional composition comprising a and b (or taking another composition not comprising a and b) is M, and the improvement as compared to the human taking the nutritional composition comprising a and b is N, then: (N-M) /N*100%is the percentage it increases.
Probiotics
Preferably, the composition comprises 103 to 1012 colony forming units per gram of composition of at least a probiotic bacteria, more preferably 104 to 1010 colony forming units per gram of composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacillus ssp., Bifidobacterium ssp., or combinations thereof.
In one embodiment, the composition comprises 1-20 wt. %of at least a probiotic bacteria, based on dry weight of the composition, more preferably 3-15 wt. %of at least a probiotic bacteria, based on dry weight of the composition.
In another embodiment, the composition comprises 25-250 mg of at least a probiotic bacteria per gram of the composition, more preferably 50-150 mg of at least a probiotic bacteria per gram of the composition.
The daily dose of the at least one probiotic bacteria in the composition according to the invention in an amount from 103 to 1012 colony forming units, preferably 108 to 1011 colony forming units.
In a preferred embodiment of the invention, the composition comprises at least one species of Lacticaseibacillus ssp. Preferably Lacticaseibacillus ssp present in the composition is selected from the group comprising: Lacticaseibacillus paracasei, Lacticaseibacillus acidophillus, Lacticaseibacillus murinus, Lacticaseibacillus reuteri, Lacticaseibacillus rhamnosus, or mixtures thereof. Preferably, the probiotic bacteria comprises Lacticaseibacillus paracasei subsp. paracasei, more preferably Lacticaseibacillus paracaseisubsp. paracasei CRL 431.
The composition may comprise at least one species of Bifidobacterium ssp. Preferred species of Bifidobacterium ssp. Include: Bifidobacterium adolescentis, Bifidobacterium longum subsp. longum, Bifidobacterium subsp. infantis, Bifidobacterium pseudolongum, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium animalis subsp. lactis, Bifidobacterium breve, and mixtures thereof. In a preferred embodiment, the Bifidobacterium ssp. is Bifidobacterium lactis BB12 (as deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under deposit number DSM 15954) , commercially available by Christian Hansen company of Denmark under the trade mark Bb12.
In a particularly preferred embodiment of the invention, the composition comprises at least one species of Lactobacillus ssp. and one species of Bifidobacterium ssp. More preferably, the composition comprises a mixture of Lacticaseibacillus paracasei subsp. paracasei CRL 431 and Bifidobacterium lactis BB12.
Prebiotic fibres
The composition comprises carbohydrates, including the prebiotic fibres.
Preferably, the composition comprises ≥ 11 wt%of prebiotic fibres, more preferably ≥30 wt%, even more preferably ≥40 wt%, especially more preferably 60-90 wt%of prebiotic fibre based on total weight of the composition.
Preferably, total carbohydrates are present in an amount ranging from 40 –98 wt. %by weight of total composition, more preferably 50-95 wt. %by weight of total composition.
Carbohydrates used herein include sugars and sugar derivatives, simple and complex sugars, and sugar-rich ingredients. Preferably, the composition comprises sugar-rich ingredients such as honey powder, juice powder, etc. preferably, the composition comprises 1-15wt%, preferably 2-13wt%of honey powder, based on total weight of the composition. The composition may further comprise 1-10wt%juice powder, more preferably 2-8wt%of a juice powder, based on total weight. A preferred juice powder is acerola juice powder.
In a preferred embodiment, the composition does not comprise lactose and milk-derived carbohydrates, preferably the composition does not comprise lactose.
Preferred prebiotics are sialo-oligosaccharides (SOS) , fructo-oligosaccharides (FOS) , galacto-oligosaccharides (GOS) , isomalto-oligosaccharides (IMO) , xylo-oligosaccharides (XOS) , arabino-xylo oligosaccharides (AXOS) , mannan oligosaccharides (MOS) , oligosaccharides of soy, glycosylsucrose (GS) , lactosucrose (LS) , sialyl-lactose (SL) Fucosyl-lactose (FL) , Lacto-N-Neotetraose (LNNT) , lactulose (LA) , palatinose-oligosaccharides (PAO) , malto-oligosaccharides, gums and/or hydrolysates thereof, pectins, starches, and/or hydrolysates thereof.
The prebiotic fibres are preferably soluble prebiotic fibres. “Soluble prebiotic fibres” , herein also referred to non-digestible fibres, are beneficially affect the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria in the colon, and thus improving host health. Such ingredients are non-digestible in the sense that they are not broken down and absorbed in the stomach or small intestine and thus pass intact to the colon where they are selectively fermented by the beneficial bacteria.
Preferred soluble prebiotic fibres are selected from fructooligasaccharides, inulin, galactooligasacharides, β-glucans (preferably yeast or oat β-glucans, more prefera-bly oat β-glucans) , or combinations thereof. In a particularly preferred embodiment, the composition comprises at least one of inulin, fructooligasaccharides and oat β-glucans, more preferably the composition comprises inulin, fructooligasaccharides and oat β-glucans. Commercially available sources include short chain fructo-oligosaccharides such as the product sold under the trade markand inu-lin such as the product sold under the trade mark
In a further aspect, the invention relates to a composition comprising:
i. at least 40 wt. %carbohydrates, based on total composition,
ii. ≥85 wt. %prebiotic soluble fibres, based on total weight of carbohydrates,
iii. 103 to 1012 colony forming units per gram of composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacillus ssp., Bifidobacterium ssp., or combinations thereof
wherein the composition does not comprise lactose.
Preferably, the composition comprises 45-95 wt. %carbohydrates, more preferably 50-80 wt. %, even more preferably at least 70 wt. %carbohydrates based on total composition.
Based on total weight of carbohydrates, the composition preferably comprises at least 90 wt. %prebiotic soluble fibres, more preferably at least 95 wt. %prebiotic sol-uble fibres, even more preferably at least 98 wt. %prebiotic soluble fibres.
In a preferred embodiment, the composition comprises 0-15 wt. %lipids, based on total composition, preferably less than 10 wt. %lipids based on total composition, more preferably less than 5 wt. %lipids based on total composition. In a particularly preferred embodiment, the composition is substantially free of lipids, for instance, no added lipids is present in the composition and only trace amounts present via other ingredients could be detectable.
According to a preferred embodiment, the composition comprises honey powder 1-15wt%, preferably 2-13wt%of honey powder, based on total weight of the composi-tion.
The composition may further comprise 1-10wt%juice powder, more preferably 2-8wt%of a juice powder, based on total weight. A preferred juice powder is acerola juice powder.
Uses and applications
The composition of the invention has been surprisingly found to significantly improve pre-sleep relaxation, reduce psychological stress, improve mood in adults subjected to administration of the composition. Also, skin dullness and pore size were im-proved, as well as a noticeable reduction on halitosis.
Preferably, the human subject is selected from a toddler, adolescent or adult. Ac-cordingly, the composition according to the invention is for administration in a human older than 3 years of age, preferably older than 6 years of age, more preferably older than 12 years of age, more preferably older than 16 years of age.
In a particularly preferred embodiment, the human subject is an adult older than 18 years of age, preferably older than 30 years of age, more preferably older than 45 years of age, even more preferably older than 55 years of age.
The composition is preferably administered to the human subject in a fasting state, preferably a fasting state of at least 8 hours, more preferably 10-14 hours. For ex-ample, the composition can be administered in the morning, e.g. after 8 hours of the last meal or dinner. Preferably, the composition is administered before 7 am in a fasting state.
Preferably, the composition is to be administered once a day. The composition is preferably administered for a period of at least 7 days, more preferably at least 14 days, even more preferably at least 30 days.
The composition of the invention is preferably a powder or a ready-to-drink bever-age, preferably a powder. The powder is preferably reconstituted in water or liquid foods, for instance, warm water. However, the powder is suitable for reconstitution in animal or vegetable milk, beverages, yoghurt, soup, cereals, warm or cold food, and the like. The composition may also be presented as a liquid suspension, a tablet, gum, candy, nutritional supplement, and the like.
The invention is herein described by means of the following illustrative, non-limiting examples.
Examples
Example 1
A synbiotic supplement according to the invention can be prepared by dry-blending. The composition is shown in Table 1.
Table 1
Example 2
Healthy volunteers (n=209) were subjected to a study including administration of the composition according to Example 1 for a period of 14 days. The human volunteers were aged between 40-60 years old (mean of 49 years) wherein 49%were male and 51%were female participants.
Before start of the study, the volunteers were asked to assess different parameters of their health status using a questionnaire. The product according to Example 1 was recommended to be consumed in the morning, thus with a minimum of 8 hours fasting, diluted in water at around 30 ℃. At day 7 and at day 14 day, the volunteers were asked to reassess the healthy status. The percentage of the studied subjects indicating to observe the present of a given parameter is provided in ‘Day 0’ . The percentage of observed improvement is indicated in col. Day 7 and day 14. The results are shown in table 2 below.
Table 2
Claims (23)
- An enteral composition for use in preventing and/or treating insomnia or sleep disorders in a human subject,the composition comprising:a. 103 to 1012 colony forming units per gram of composition of at least a probiotic bacteria selected from the group comprising: Lac-ticaseibacillus ssp., Bifidobacterium ssp., or combinations thereof; and, optionally,b. ≥ 11 wt%prebiotic fibre based on the total weight of the composi-tion.
- The enteral composition according to claim 1, wherein the daily dose of the at least one probiotic bacteria is from 103 to 1012 colony forming units, preferably 108 to 1011 colony forming units.
- The enteral composition according to any of the preceding claims, where-in the composition does not comprise lactose.
- The enteral composition according to any of the preceding claims, where-in the composition comprises at least one species of Lacticaseibacillus ssp, preferably selected from Lacticaseibacillus paracasei, Lacticaseiba-cillus acidophillus, Lacticaseibacillus murinus, Lacticaseibacillus reu-teri, Lacticaseibacillus rhamnosus, or mixtures thereof.
- The enteral composition according to any of the preceding claims, wherein Lacticaseibacillus ssp. is Lacticaseibacillus paracasei, preferably Lacticaseibacillus paracasei subsp. paracasei, more preferably Lacticaseibacillusparacasei subsp. paracasei CRL 431.
- The enteral composition according to any of the preceding claims, where-in the composition comprises at least one species of Bifidobacterium ssp., preferably selected from Bifidobacterium adolescentis, Bifidobacterium longum subsp. longum, Bifidobacterium subsp. infantis, Bifidobacterium pseudolongum, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium breve, and mixtures thereof.
- The enteral composition according to any of the preceding claims, where-in the Bifidobacterium ssp. is Bifidobacterium lactis, preferably Bifidobacterium lactis BB12.
- The enteral composition according to any of the preceding claims, where-in the composition comprises Lactobacillus ssp. and Bifidobacterium ssp.
- The enteral composition according to any of the preceding claims, where-in the prebiotic fibre, preferably soluble prebiotic fibres is selected from fructooligasaccharides, inulin, galactooligasacharides, β-glucans, or com-binations thereof.
- The enteral composition according to any of the preceding claims, where-in the composition is administered to a human subject in fasting state.
- The enteral composition according to any of the preceding claims, where-in fasting is at least 8 hours, preferably 10-14 hours.
- The enteral composition according to any of the preceding claims, where-in the human subject is an adult, preferably ≥30 years old adult.
- The enteral composition according to any of the preceding claims, where-in the composition is administered once a day.
- The enteral composition according to any of the preceding claims, where-in the composition is administered for a period of at least 7 days, prefera-bly at least 14 days.
- The enteral composition according to any of the preceding claims, where-in the composition is a powder, preferably a powder to be reconstituted in warm water.
- The enteral composition according to any of the preceding claims, where-in comparing a human not taking a nutritional composition comprising a and b, the prevention and/or treatment is improved in ≥ 2%, preferably ≥5%.
- Non-therapeutic method of improving sleep quality, and/or inducing and/or enhancing pre-sleep relaxation, the method comprising administra-tion of an enteral composition to a human subject in need thereof, where-in the composition comprises:a. 103 to 1012 colony forming units per gram of composition of at least a probiotic bacteria selected from the group comprising: Lac-ticaseibacillus ssp., Bifidobacterium ssp., or combinations thereof; andb. ≥ 11 wt%prebiotic fibre based on the total weight of the composi-tion.
- The non-therapeutic method of claim 17, wherein improvement and/or enhancement is with respect to a human not taking a nutritional composition comprising a and b, wherein the improvement and/or enhancement is ≥2%, preferably ≥5%.
- Non-therapeutic method of reducing halitosis, the method comprising administration of an enteral composition to a human subject in need thereof, wherein the composition comprises:a. 103 to 1012 colony forming units per gram of composition of at least a probiotic bacteria selected from the group comprising: Lac-ticaseibacillus ssp., Bifidobacterium ssp., or combinations thereof; andb. ≥ 11 wt%prebiotic fibre based on the total weight of the composi-tion.
- Non-therapeutic method of improving skin appearance and texture, the method comprising administration of an enteral composition to a human subject in need thereof, wherein the composition comprises:a. 103 to 1012 colony forming units per gram of composition of at least a probiotic bacteria selected from the group comprising: Lac-ticaseibacillus ssp., Bifidobacterium ssp., or combinations thereof; andb. ≥ 11 wt%prebiotic fibre based on the total weight of the composi-tion.
- An enteral composition comprising:i. at least 40 wt. %carbohydrates, based on total composition,ii. ≥85 wt. %prebiotic soluble fibres, based on total weight of carbohydrates,iii. 103 to 1012 colony forming units per gram of composition of at least a probiotic bacteria selected from the group comprising: Lacticaseibacillus ssp., Bifidobacterium ssp., or combinations thereofwherein the composition does not comprise lactose.
- Use of a composition as defined in any of claims 1 to 16 in the manufac-ture of an enteral product for preventing and/or treating insomnia or sleep disorders in a human subject, the composition comprising:a. 103 to 1012 colony forming units per gram of composition of at least a probiotic bacteria selected from the group comprising: Lac-ticaseibacillus ssp., Bifidobacterium ssp., or combinations thereof; and, optionally,b. ≥ 11 wt%prebiotic fibre based on the total weight of the composi-tion.
- The use of claim 22 wherein comparing a human not taking the composi-tion comprising a and b, the prevention and/or treatment is improved in ≥2%, preferably ≥ 5%.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2022/099108 | 2022-06-16 | ||
| CN2022099108 | 2022-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023241390A1 true WO2023241390A1 (en) | 2023-12-21 |
Family
ID=89192112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2023/098264 WO2023241390A1 (en) | 2022-06-16 | 2023-06-05 | Compositions and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023241390A1 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998026787A1 (en) * | 1996-12-19 | 1998-06-25 | The University Of New South Wales | Prebiotics and probiotics |
| CN101095698A (en) * | 2006-06-26 | 2008-01-02 | 青岛东海药业有限公司 | Probiotics and prebiotics for preventing and treating foetid faeces and foetid faeces poisoning syndrome and the composition preparations thereof |
| CN101155616A (en) * | 2005-04-08 | 2008-04-02 | 宝洁公司 | Methods of use of probiotic bifidobacteria for human beauty benefits |
| CN106860483A (en) * | 2017-01-06 | 2017-06-20 | 家家乐购（北京）科技有限公司 | Probiotics complex composition and application containing Bifidobacterium and lactobacillus acidophilus |
| CN108244655A (en) * | 2018-02-02 | 2018-07-06 | 云南中京国建投资有限公司 | A kind of tranquilizing the mind, antidepressant symphysis unit composition and its preparation and application |
| CN108671135A (en) * | 2018-08-01 | 2018-10-19 | 泰安大凡神农生物有限公司 | A kind of Traditional Chinese medicine probiotic compound of conditioning insomnia and depression |
| CN110051003A (en) * | 2019-04-24 | 2019-07-26 | 广州能靓生物技术有限公司 | A kind of compound probiotic composition and its application |
-
2023
- 2023-06-05 WO PCT/CN2023/098264 patent/WO2023241390A1/en unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998026787A1 (en) * | 1996-12-19 | 1998-06-25 | The University Of New South Wales | Prebiotics and probiotics |
| CN101155616A (en) * | 2005-04-08 | 2008-04-02 | 宝洁公司 | Methods of use of probiotic bifidobacteria for human beauty benefits |
| CN101095698A (en) * | 2006-06-26 | 2008-01-02 | 青岛东海药业有限公司 | Probiotics and prebiotics for preventing and treating foetid faeces and foetid faeces poisoning syndrome and the composition preparations thereof |
| CN106860483A (en) * | 2017-01-06 | 2017-06-20 | 家家乐购（北京）科技有限公司 | Probiotics complex composition and application containing Bifidobacterium and lactobacillus acidophilus |
| CN108244655A (en) * | 2018-02-02 | 2018-07-06 | 云南中京国建投资有限公司 | A kind of tranquilizing the mind, antidepressant symphysis unit composition and its preparation and application |
| CN108671135A (en) * | 2018-08-01 | 2018-10-19 | 泰安大凡神农生物有限公司 | A kind of Traditional Chinese medicine probiotic compound of conditioning insomnia and depression |
| CN110051003A (en) * | 2019-04-24 | 2019-07-26 | 广州能靓生物技术有限公司 | A kind of compound probiotic composition and its application |
Non-Patent Citations (1)
| Title |
|---|
| HU, XUEZHI: "The market and application of probiotic bacteria and probiotics in Japan", JIANGSU CONDIMENT AND SUBSIDIARY FOOD, vol. 26, no. 1, 31 December 2009 (2009-12-31), pages 1 - 4, XP009551613, ISSN: 1006-8481, DOI: 10.16782/j.cnki.32-1235/ts.2009.01.001 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2517616C2 (en) | Nourishing composition, including probiotics and improving sleep pattern | |
| EP2990045B1 (en) | Bifidobacterium animalis subsp. lactis for use in decreasing abdominal pain in a postmenopausal woman | |
| JP6796070B2 (en) | Foods and drinks containing indigestible components and hydrogen gas producing agents in the large intestine | |
| KR20140131505A (en) | Lactobacillus reuteri DSM 17938 for the development of cognitive function | |
| CN108541951A (en) | A kind of symphysis unit composition and its preparation for preventing senile dementia, enhancing memory | |
| Tulk et al. | Daily consumption of a synbiotic yogurt decreases energy intake but does not improve gastrointestinal transit time: a double-blind, randomized, crossover study in healthy adults | |
| CN115226773A (en) | Composite probiotic sleep-aiding solid beverage and preparation method thereof | |
| WO2023241390A1 (en) | Compositions and uses thereof | |
| ES2763874B2 (en) | PHASCOLARCTOBACTERIUM FAECIUM FOR USE IN THE PREVENTION AND TREATMENT OF OBESITY AND ITS COMORBIDITIES | |
| EP2323675B1 (en) | Compositions comprising lactobacillus casei cncm i-1518 (dn-114001) for prevention or treatment of an upper respiratory tract infection in smokers | |
| US9937213B2 (en) | Composition comprising L. rhamnosus GG | |
| CN109010356A (en) | Adjust intestinal flora and the anti-composition to treat constipation and its application | |
| WO2024009689A1 (en) | Bowel movement ameliorant | |
| WO2024013393A1 (en) | Combination of bifidobacterium and fucosylated hmo for use in increasing nmn or nad+ | |
| JP2023106626A (en) | Lactic acid bacteria and serotonin secretion promoter | |
| CN112401180A (en) | Natural fruit powder synbiotics buccal tablets and preparation method thereof | |
| TW202408556A (en) | Bowel movement ameliorant | |
| WO2023237306A1 (en) | Nutritional composition comprising gos and hmos | |
| CN113573721A (en) | Mixture of probiotic strains for the treatment of allergic asthma and recurrent wheezing, preferably for pediatric subjects | |
| Vlieger et al. | Tolerance and safety of L. paracasei ssp. paracasei in combination with B. animalis ssp. lactis in a prebiotic-containing infant formula: a randomized controlled trial | |
| Thibault et al. | EFFECTS OF LONG-TERM CONSUMPTION OF A FERMENTED INFANT FORMULA ON ACUTE DIARRHOEA IN HEALTHY INFANTS | |
| Dupont | PEG versus lactulose in childhood constipation | |
| Gibson | The role of long-chain polyunsaturated fatty acids in infancy | |
| Walker | BACTERIAL COLONIZATION AND THE DEVELOPMENT OF INTESTINAL DEFENSES | |
| Di Lorenzo | Movements of a constipated intestine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23822959 Country of ref document: EP Kind code of ref document: A1 |